Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 3/20 | 0.38 |
| ▸ | BCHE | P06276 | 2/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19667585 | 0.86 | GPR119 (0.42) | NAMPTHTR6BCHEGPR119 | |
| SCHEMBL19679356 | 0.82 | NAMPT (0.41) | NAMPTGPR119 | |
| SCHEMBL19667612 | 0.82 | NAMPT (0.41) | NAMPTGPR119 | |
| SCHEMBL23735237 | 0.82 | NAMPT (0.41) | NAMPTGPR119 | |
| SCHEMBL19684748 | 0.80 | PRKCA (0.36) | ALDH1A1HPGDPDE4BCNR2 | |
| SCHEMBL19684900 | 0.79 | KCNH2 (0.40) | — | |
| SCHEMBL19684899 | 0.70 | PRKCA (0.38) | CNR2 | |
| SCHEMBL19684931 | 0.69 | CSF1R (0.39) | ALDH1A1HPGDPDE4BGPR119PDE4A | |
| SCHEMBL5450422 | 0.69 | ABHD6 (0.56) | NAMPTHTR6BCHE | |
| SCHEMBL7901250 | 0.69 | HTR6 (0.45) | ALDH1A1HTR6BCHEGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | ALDH1A1 2669/4885HPGD 1619/4885NAMPT 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.